Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the
reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
Patients who are exclusively on liquid food should not use odevixibat.
- TRADE NAME: Bylvay (Albireo)
- INDICATIONS: Treatment of pruritus in patients with progressive familial intrahepatic cholestasis.
- CLASS: Bile acid transporter inhibitor
- HALF-LIFE: 2.4 hours
- FDA APPROVAL DATE: 07/20/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bile acid sequestrant - PREGNANCY: No human data on use in pregnant persons in order to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
